Emerging multimodal nanomedicines for breast cancer based on two novel drug encapsulation concepts: mesoporous organosilica drugs and drug structure-directing agents

• Autores: Eva Romaní Cubells
• Directores de la Tesis: Raúl Sanz Martín (dir. tes.), Rafael Ángel García Muñoz (dir. tes.)
• Lectura: En la Universidad Rey Juan Carlos ( España ) en 2024
• Idioma: español
• Tribunal Calificador de la Tesis: David Pedro Serrano Granados (presid.), María Ventura Sánchez-Horneros (secret.), Blanca González Ortiz (voc.), María Teresa Simón Yarza (voc.), Ramón Martínez Máñez (voc.)
• Programa de doctorado: Programa de Doctorado en Tecnologías Industriales: Química, Ambiental, Energética, Electrónica, Mecánica y de los Materiales por la Universidad Rey Juan Carlos
• Menciones:
  • Internacional
• Calificación: Sobresaliente Cum Laude
• Enlaces
  • Tesis en acceso abierto en: TESEO
• Resumen

  • Cancer causes millions of deaths worldwide each year. Chemotherapy, the treatment of choice in metastatic cancers, presents serious toxicity problems compromising patients' quality of life and limiting the dose that can be administered and, therefore, its therapeutic efficacy. Besides, chemotherapies usually present short half-lives. Nanomedicine is a promising tool to solve these problems: the encapsulation of chemotherapeutic drugs in nanocarriers allow to protect and to selectively deliver them to cancer cells, thus increasing drug efficacy while avoiding side effects. However, avoiding premature drug release from nanocarriers is a challenge. In this thesis, two novel encapsulation concepts have been developed for breast cancer treatment: Mesoporous Organosilica Drug nanoparticles (MODs) and Drug Structure-Directing Agents (DSDAs). These multimodal nanomedicines allow to significantly reduce drug leakage, and in vivo experiments showed a higher therapeutic efficacy and better safety profile than conventional treatment.